Date: 2014-12-15
Type of information: Private placement
Company: BerGenBio (Norway)
Investors:
Amount: NOK90 million ($15 million - €9.8 million)
Funding type: private placement
Planned used: BerGenBio will use the proceeds from the financing to support the development of its pipeline of cancer therapeutics, in particular an enlarged clinical development program for its lead drug candidate, BGB324, a first-in-class selective Axl kinase inhibitor, which is currently in Phase 1b clinical trials for patients with acute myeloid leukaemia (AML). The company intends to evaluate its lead product in additional Phase 1 and Phase 2 clinical trials starting in 2015. The on-going Phase 1b trial in AML is expected to report towards the end of 2015 and BergenBio will start enrolling patients in non-small-cell-lung-cancer.
Others: *On December 15, 2014, BerGenBio, a biopharmaceutical company focused on developing innovative drugs for aggressive drug resistant cancers, announced that it has raised NOK90 million (c. $15 million) in a private placing from new and existing investors. Arctic Securities AS acted as sole bookrunner for the private placement.
Therapeutic area: Cancer - Oncology - Rare diseases
